Your browser is no longer supported. Please, upgrade your browser.
Settings
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own1.10% Shs Outstand165.06M Perf Week8.53%
Market Cap3.76B Forward P/E- EPS next Y-0.74 Insider Trans-6.09% Shs Float148.00M Perf Month33.84%
Income-210.10M PEG- EPS next Q-0.18 Inst Own76.20% Short Float19.20% Perf Quarter31.75%
Sales2.40M P/S1566.69 EPS this Y-135.30% Inst Trans0.77% Short Ratio13.90 Perf Half Y106.72%
Book/sh0.44 P/B51.77 EPS next Y53.10% ROA-98.60% Target Price22.33 Perf Year204.95%
Cash/sh2.17 P/C10.48 EPS next 5Y- ROE- 52W Range7.17 - 23.18 Perf YTD40.97%
Dividend- P/FCF- EPS past 5Y-44.67% ROI-200.90% 52W High-1.73% Beta1.48
Dividend %- Quick Ratio3.90 Sales past 5Y-37.60% Gross Margin72.70% 52W Low217.71% ATR0.96
Employees138 Current Ratio3.90 Sales Q/Q-61.50% Oper. Margin- RSI (14)81.39 Volatility3.61% 5.16%
OptionableYes Debt/Eq2.78 EPS Q/Q61.10% Profit Margin- Rel Volume0.73 Prev Close22.58
ShortableYes LT Debt/Eq2.78 EarningsMay 09 AMC Payout- Avg Volume2.04M Price22.78
Recom1.30 SMA2017.17% SMA5032.82% SMA20060.85% Volume1,486,643 Change0.89%
May-05-17Upgrade Wells Fargo Market Perform → Outperform
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Jul-29-15Downgrade Jefferies Buy → Hold
Aug-27-14Downgrade R. F. Lafferty Buy → Neutral $4
Jan-08-14Initiated Chardan Capital Markets Buy $9
Oct-02-13Reiterated Oppenheimer Outperform $6 → $8
Sep-10-13Initiated R. F. Lafferty Buy $8
Jun-03-13Initiated WallachBeth Buy $6
Aug-31-11Initiated Summer Street Research Buy $8
Jul-28-11Initiated Summer Street Research Buy $8
Jul-13-11Resumed Brean Murray Buy $8
May-17-11Initiated Oppenheimer Outperform $6
Feb-23-11Initiated Wedbush Outperform $6
Jul-03-07Initiated Brean Murray Buy $8
Feb-20-07Initiated Lazard Capital Buy $6
May-21-18 08:00AM  Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration GlobeNewswire
May-18-18 04:03AM  Edited Transcript of IMMU earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-17-18 12:43PM  Immunomedics Inc (NASDAQ:IMMU): Time For A Financial Health Check Simply Wall St. +7.12%
08:00AM  Today's Research Reports on Trending Tickers: Immunomedics and Rite Aid ACCESSWIRE
May-16-18 05:01PM  Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer GlobeNewswire
May-09-18 04:24PM  Immunomedics: Fiscal 3Q Earnings Snapshot Associated Press
04:00PM  Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
07:30AM  Analysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics  Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-02-18 12:01PM  Harry Boxers four biotech stocks to watch today MarketWatch
08:00AM  Immunomedics to Report Third Quarter Fiscal 2018 Results and Host Conference Call and Webcast on May 9, 2018 GlobeNewswire
May-01-18 08:45AM  Immunomedics (IMMU) in Focus: Stock Moves 7.9% Higher Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Heat Biologics and Immunomedics ACCESSWIRE
Apr-25-18 12:15PM  Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-17-18 10:21AM  When Will Immunomedics Inc (NASDAQ:IMMU) Become Profitable? Simply Wall St.
Apr-13-18 08:20AM  Todays Research Reports on Trending Tickers: Exact Sciences and Immunomedics ACCESSWIRE
Apr-11-18 08:30AM  Todays Research Reports on Trending Tickers: Neuralstem and Immunomedics ACCESSWIRE
Apr-09-18 08:00AM  Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer GlobeNewswire
Mar-27-18 08:25AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics ACCESSWIRE
Mar-05-18 08:00AM  Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-26-18 06:06PM  Edited Transcript of IMMU earnings conference call or presentation 8-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Feb-15-18 08:00AM  Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
07:30AM  Fennec Pharma (FENC): The Most Likely Acquisition Target in Healthcare with 200-300% Upside? ACCESSWIRE
Feb-14-18 07:30AM  Blog Exposure - FDA Accepts Amicus Therapeutics NDA for Migalastat for Treatment of Fabry Disease ACCESSWIRE
Feb-13-18 03:49PM  8 Companies That Could Disappear by 2019 InvestorPlace
Feb-09-18 05:01AM  Immunomedics reports 2Q loss Associated Press
Feb-08-18 04:15PM  Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
Feb-06-18 08:00AM  Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018 GlobeNewswire
Jan-31-18 08:20AM  New Research: Key Drivers of Growth for Cavco Industries, National Commerce, The Providence Service, Cisco, Immunomedics, and Emergent Biosolutions Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-17-18 07:00AM  Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock InvestorPlace
Jan-11-18 08:00AM  Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer GlobeNewswire
Jan-10-18 08:00AM  Todays Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics ACCESSWIRE
Jan-08-18 08:30AM  Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million GlobeNewswire
Jan-04-18 08:45AM  Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 11:34AM  Harry Boxer: These two marijuana stocks are climbing higher MarketWatch
Dec-22-17 11:41AM  ETFs with exposure to Immunomedics, Inc. : December 22, 2017 Capital Cube +6.08%
Dec-21-17 12:23PM  BlackBerry Among Four Stocks Breaking Out Forbes
Dec-13-17 07:02AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-11-17 01:59PM  ETFs with exposure to Immunomedics, Inc. : December 11, 2017 Capital Cube
Dec-08-17 01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace
07:45AM  Immunomedics' Data Is Good News for Seattle Genetics, Too Motley Fool
07:16AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017 Capital Cube
Dec-07-17 08:10AM  Todays Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals ACCESSWIRE +16.16%
Dec-06-17 03:58PM  Why Immunomedics, Inc. Is Soaring Today Motley Fool +13.00%
12:10PM  Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) GlobeNewswire
Nov-30-17 02:00PM  ETFs with exposure to Immunomedics, Inc. : November 30, 2017 Capital Cube
Nov-29-17 08:04AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017 Capital Cube
Nov-28-17 08:05AM  Immunomedics, Full Study Data to be Presented December 6, 2017, BLA Application as Early as 1Q18 ACCESSWIRE
Nov-27-17 08:05AM  Analysis: Positioning to Benefit within Aradigm, General Motors, AT&T, Denbury Resources, Novavax, and Immunomedics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-20-17 07:40AM  Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine ACCESSWIRE
Nov-16-17 08:43AM  Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock Zacks +8.11%
Nov-15-17 08:38AM  Immunomedics (IMMU) Jumps: Stock Rises 5.4% Zacks +5.31%
Nov-14-17 04:07PM  Edited Transcript of IMMU earnings conference call or presentation 9-Nov-17 10:00pm GMT Thomson Reuters StreetEvents +5.40%
12:44PM  Cowen Bets on Immunomedics Securing Accelerated Approval Even After Decreased Overall Survival Seen in IMMU-132 Abstract SmarterAnalyst
Nov-13-17 04:30PM  Why Sears Holdings, Immunomedics, and J.C. Penney Slumped Today Motley Fool -19.35%
09:30AM  Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium GlobeNewswire
07:24AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : November 13, 2017 Capital Cube
Nov-10-17 03:02PM  Why Immunomedics, Inc. Jumped Higher Today Motley Fool +18.77%
08:20AM  Todays Research Reports on Trending Tickers: Endo International and Immunomedics ACCESSWIRE
Nov-09-17 05:21PM  Immunomedics reports 1Q loss Associated Press
04:10PM  Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
04:05PM  Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth GlobeNewswire
01:00PM  Immunomedics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 08:00AM  Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017 GlobeNewswire +6.82%
Oct-31-17 12:13PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : October 31, 2017 Capital Cube -5.13%
11:42AM  ETFs with exposure to Immunomedics, Inc. : October 31, 2017 Capital Cube
Oct-30-17 08:11AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : October 30, 2017 Capital Cube
Oct-27-17 09:35AM  Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers TheStreet.com +6.18%
Oct-23-17 08:37AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks
Oct-05-17 12:21PM  Edited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT Thomson Reuters StreetEvents -8.50%
Oct-03-17 11:19AM  ETFs with exposure to Immunomedics, Inc. : October 3, 2017 Capital Cube
Sep-15-17 04:30PM  Why Carnival, Immunomedics, and Fitbit Slumped Today Motley Fool
08:00AM  Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock GlobeNewswire
Sep-11-17 09:00AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks +5.17%
07:00AM  Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer GlobeNewswire
Aug-30-17 08:00AM  Immunomedics to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-28-17 05:33PM  ETFs with exposure to Immunomedics, Inc. : August 28, 2017 Capital Cube +14.07%
03:30PM  Here's Why Immunomedics Rose as Much as 14.2% Today Motley Fool
Aug-24-17 12:51PM  Harry Boxer: These three biotech stocks are breaking out MarketWatch +9.88%
10:45AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q4, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-23-17 08:48AM  Immunomedics (IMMU) Catches Eye: Stock Up 5.1% Zacks
08:41AM  Zacks.com featured highlights: Glu Mobile, Calumet Specialty Products Partners, The Bancorp, Immunomedics and Hudbay Minerals Zacks
Aug-22-17 10:44AM  Immunomedics' Progress in Phase II Cancer Study Encouraging Zacks +5.11%
08:23AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : August 22, 2017 Capital Cube
Aug-21-17 02:02PM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: 2017 By the Numbers : August 21, 2017 Capital Cube +7.01%
08:00AM  Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer GlobeNewswire
Aug-17-17 08:50AM  Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? Zacks
Aug-16-17 09:21PM  Immunomedics, Inc. Value Analysis (NASDAQ:IMMU) : August 17, 2017 Capital Cube
09:14PM  Immunomedics reports 4Q loss Associated Press
04:00PM  Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline GlobeNewswire
Aug-07-17 04:00PM  Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2017 Results GlobeNewswire
Aug-03-17 09:46AM  Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : August 3, 2017 Capital Cube
Jul-10-17 02:40PM  ETFs with exposure to Immunomedics, Inc. : July 10, 2017 Capital Cube
09:00AM  Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers GlobeNewswire
Jun-29-17 03:11PM  Immunomedics Announces Results of Special Stockholder Meeting GlobeNewswire
08:35AM  Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock Zacks
Jun-27-17 03:20PM  ETFs with exposure to Immunomedics, Inc. : June 27, 2017 Capital Cube
Jun-16-17 03:54PM  ETFs with exposure to Immunomedics, Inc. : June 16, 2017 Capital Cube
Jun-07-17 11:05AM  Three Junior Biotechs Ready to Run Investopedia
Jun-05-17 02:22PM  ETFs with exposure to Immunomedics, Inc. : June 5, 2017 Capital Cube
Jun-01-17 08:00AM  Immunomedics to Present at Jefferies 2017 Global Healthcare Conference GlobeNewswire
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDENBERG DAVID MDirectorMar 07Sale17.6840,000707,0005,613,252Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorMar 07Sale17.5020,000350,0001,774,285Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorMar 05Sale17.2440,000689,4005,653,252Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorFeb 28Sale17.0917,729302,9895,693,252Mar 12 08:32 PM
MARKISON BRIAN ADirectorNov 20Option Exercise3.1615,00047,40099,178Nov 21 05:00 PM
MARKISON BRIAN ADirectorNov 20Sale11.898,39099,72490,788Nov 21 05:00 PM
venBio Select Advisor LLCDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 15 05:48 PM
venBio Select Advisor LLCDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 15 05:48 PM
GOLDENBERG CYNTHIA LDirectorSep 01Sale12.9010,000129,000778,219Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksSep 01Sale12.9010,000129,0003,395,578Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorAug 31Sale12.3810,000123,750788,219Sep 05 07:10 PM
GOLDENBERG DAVID MSee RemarksAug 31Sale12.3810,000123,7503,405,578Sep 05 07:10 PM
GOLDENBERG CYNTHIA LDirectorAug 28Sale11.5215,000172,841798,219Aug 28 08:54 PM
GOLDENBERG DAVID MSee RemarksAug 28Sale11.5610,000115,5913,415,578Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 24Sale10.2425,000256,105813,219Aug 28 08:54 PM
GOLDENBERG CYNTHIA LDirectorAug 23Sale9.5010,00095,000838,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 23Sale9.5010,00095,0003,455,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 22Sale9.5010,00095,000848,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 22Sale9.5010,00095,0003,465,578Aug 23 09:00 PM
GOLDENBERG CYNTHIA LDirectorAug 21Sale8.9720,000179,426858,219Aug 23 09:00 PM
GOLDENBERG DAVID MSee RemarksAug 21Sale8.9720,000179,4263,475,578Aug 23 09:00 PM